Scanning the horizon—Development and implementation of an early awareness system for anticancer drugs in Austria

Nachtnebel, A.; Geiger-Gritsch, S.; Hintringer, K.; Wild, Claudia

doi:10.1016/j.healthpol.2011.11.003

Cited by 21 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As mentioned, funding new effective treatments for patients with HCV is a growing concern with more than150 to 185 million people worldwide believed to be infected with chronic HCV, high cure rates with second generation directly acting antivirals (DAAs) and associated costs (6,14,84,85). For instance in Malaysia, the prevalence of HCV is estimated at 1.5% of the population (86).…”

Section: Ii) New Treatments For Patients With Hepatitis C Virus (Hcv)mentioning

confidence: 99%

“…For instance in Malaysia, the prevalence of HCV is estimated at 1.5% of the population (86). The primary goal of treatment is to cure the infection, defined as a sustained virological response (SVR) (14,40,87). Previous treatments have included pegylated interferon and ribavirin and more recently bocepravir and telapravir, first generation DAAs (6,14).…”

Section: Ii) New Treatments For Patients With Hepatitis C Virus (Hcv)mentioning

confidence: 99%

“…However, we are now seeing even high income countries struggling to fund new premium-priced medicines including new therapies to treat patients with cancer (4)(5)(6)(7)(8)(9). Unless these problems are addressed, the number of struggling countries will grow driven by factors including changing demographics, increasing prevalence of non-communicable diseases (NCDs), rising patient expectations and the continued launch of new premium priced technologies (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). New medicines increasingly include novel biological drugs (21), often priced at between US$100,000 -US$400,000 (Euro74,000 -296,000) per patient per course or year (8,10,18,22,23).…”

Section: Introductionmentioning

confidence: 99%

“…Funding new effective treatments for patients with hepatitis C virus (HCV) is a also growing concern given its prevalence and requested prices for new treatments (6,14,40). In some cases, concerns arise with patient safety when new medicines are used in a wider and less well-defined population than those enrolled into Phase III clinical trials (41).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Godman

Malmström

Diogène³

et al. 2014

Expert Review of Clinical Pharmacology

116

132

View full text Add to dashboard Cite

Are new models needed to optimise the utilisation of new medicines to sustain healthcare systems?Godman B 1,2,3 , Malmström RE 4 , Diogene E 5 , Gray A 6 , Jayathissa S 7 , Timoney A 8 , Acurcio FA 9,10 , Alkan A 11 , Brzezinska A 12 , Bucsics A 13 , Campbell S 14,15 AbstractIntroduction: Medicines have made an appreciable contribution to improving health. However, even high income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimise their use. Objective: Review case histories among health authorities to improve the utilisation and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. Challenges and proposed models: A number of issues and challenges have been identified including the limited innovation level of new medicines alongside increasing requested prices for their reimbursement especially for oncology, orphan diseases, diabetes and HCV. Models centre on the three pillars of pre-, peri, and post-launch including critical drug evaluation and multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure Discussion: Proposed models which involve all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

show abstract

Section: Ii) New Treatments For Patients With Hepatitis C Virus (Hcv)mentioning

confidence: 99%

Section: Ii) New Treatments For Patients With Hepatitis C Virus (Hcv)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Godman

Malmström

Diogène³

et al. 2014

Expert Review of Clinical Pharmacology

116

132

View full text Add to dashboard Cite

show abstract

“…Initiatives for new drugs include the development of new models to help optimise their use, which centre on three pillars. The three pillars include horizon scanning and budgeting pre-launch, critical drug evaluation peri-launch including possible risk-sharing arrangements, as well as monitoring of prescribing against agreed guidance post launch and, where possible, patient registries to assess the effectiveness and safety of new drugs in routine care [18,19,[58][59][60][61][62][63][64][65]. Considerable effort has been directed towards enhancing the prescribing efficiency of existing drugs, based on generics [1][2][3][4][5][6][7][8][9][10][11]15,33,40,66].…”

Section: Introductionmentioning

confidence: 99%

Essential to increase the use of generics in Europe to maintain comprehensive health care?

Godman

Bennie

Baumgärtel³

et al. 2012

112

View full text Add to dashboard Cite

INTRODUCTION: Reforms have been introduced across Europe to increase prescribing efficiency with existing drugs. These include measures to lower prices of generics as well as increase their prescribing versus originators and patented products in a class or related class. This is essential to maintain comprehensive health care in Europe given continued pressures. The alternative is insufficient funds for new innovative drugs and increasing drug volumes with ageing populations. OBJECTIVE: To review the influence of measures and initiatives to increase the prescribing and dispensing of generics at low prices on ambulatory care prescribing efficiency. In view of this, provide guidance as authorities strive to introduce further reforms to meet their goals. METHODOLOGY: A narrative review of published papers combined with case histories. RESULTS: The different supply- and demand-side measures have reduced generic prices to as low as 2% to 3% of pre-patent loss prices in some cases as well as appreciably enhanced their utilisation. As a result, prescribing efficiency has increased without compromising care. In some cases, the reforms have led to expenditure actually falling despite appreciably increased volumes. CONCLUSIONS: Increasing use of generics at low prices will help maintain the European ideals of comprehensive and equitable health care. However, countries will continually need to learn from each other.

show abstract

Marktzugang, Erstattung und Preissetzung neuer patentgeschützter Arzneimittel in der Europäischen Union

Vogler

2018

Arzneiverordnungs-Report 2018

View full text Add to dashboard Cite

Scanning the horizon—Development and implementation of an early awareness system for anticancer drugs in Austria

Cited by 21 publications

References 7 publications

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Essential to increase the use of generics in Europe to maintain comprehensive health care?

Marktzugang, Erstattung und Preissetzung neuer patentgeschützter Arzneimittel in der Europäischen Union

Contact Info

Product

Resources

About